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A unique insertion in STARD9’s motor domain 
regulates its stability
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James A. Wohlschlegelc,d,e, and Jorge Z. Torresa,d,e
aDepartment of Chemistry and Biochemistry, bProgram in Bioengineering, cDepartment of Biological Chemistry, David 
Geffen School of Medicine, dJonsson Comprehensive Cancer Center, and eMolecular Biology Institute, University of 
California, Los Angeles, Los Angeles, CA 90095
ABSTRACT STARD9 is a largely uncharacterized mitotic kinesin and putative cancer target 
that is critical for regulating pericentriolar material cohesion during bipolar spindle assembly. 
To begin to understand the mechanisms regulating STARD9 function and their importance to 
cell division, we took a multidisciplinary approach to define the cis and trans factors that 
regulate the stability of the STARD9 motor domain. We show that, unlike the other ∼50 mam-
malian kinesins, STARD9 contains an insertion in loop 12 of its motor domain (MD). Working 
with the STARD9-MD, we show that it is phosphorylated in mitosis by mitotic kinases that 
include Plk1. These phosphorylation events are important for targeting a pool of STARD9-MD 
for ubiquitination by the SCFβ-TrCP ubiquitin ligase and proteasome-dependent degrada-
tion. Of interest, overexpression of nonphosphorylatable/nondegradable STARD9-MD mu-
tants leads to spindle assembly defects. Our results with STARD9-MD imply that in vivo the 
protein levels of full-length STARD9 could be regulated by Plk1 and SCFβ-TrCP to promote 
proper mitotic spindle assembly.
INTRODUCTION
During mitosis, kinesins have critical roles in a wide array of processes 
that contribute to cell division, including spindle assembly, chromo-
some congression, and cytokinesis (Rath and Kozielski, 2012). To 
perform their functions, mitotic kinesins require ATP hydrolysis. This 
feature makes them amenable to small-molecule inhibition with ATP-
competitive or allosteric inhibitors. Not surprisingly, mitotic kinesins 
have received considerable attention as potential targets in the treat-
ment of proliferative diseases such as cancer (Rath and Kozielski, 
2012). Indeed, clinical trials are underway to test the efficacy of mi-
totic kinesin inhibitors in the treatment of cancer (Rath and Kozielski, 
2012). Recently, we identified steroidogenic acute regulatory pro-
tein–related lipid transfer (START) domain containing 9 (STARD9), a 
member of the kinesin-3 family of molecular motors, as an important 
factor for stabilization of the pericentriolar material (PCM) under 
microtubule-mediated tension in early mitosis (Torres et al., 2011). 
Depletion of STARD9 by small interfering RNA (siRNA) treatment 
leads to PCM fragmentation, multipolar spindles, failure to congress 
chromosomes, mitotic arrest, spindle assembly checkpoint activa-
tion, and a faster apoptotic cell death than current antimitotic drug 
treatments, indicating that STARD9 is a potential target for therapeu-
tic intervention (Torres et al., 2011; Torres, 2012). However, little is 
known about the molecular basis of STARD9’s mechanism of action 
and the regulatory mechanisms modulating its activity.
Although there are many mechanisms that regulate kinesin activ-
ity (including autoinhibition, perturbation of the kinesin–microtubule 
interaction, and sequestration of kinesins to specific cellular com-
partments), phosphorylation of mitotic kinesins by mitotic kinases 
(such as Plk1, Cdk1, and Aurora A/B) has emerged as a sensitive 
switch to modulate kinesin activity in a spatial-temporal manner 
(Andrews et al., 2004; Cahu et al., 2008; Jang et al., 2009; Verhey 
and Hammond, 2009). For example, Plk1 phosphorylates the kine-
sin-13 motor MCAK during mitosis to promote its microtubule-de-
polymerization activity, which is necessary for proper chromosome 
segregation (Zhang et al., 2011). Plk1 also phosphorylates factors 
important for mitotic progression (Emi1 and Bora), centrosome 
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program Modeller (Sali and Blundell, 1993; Figure 1B and Supple-
mental Figure S1). The STARD9-MD structure was evaluated with 
the structural analysis verification server and by Ramachandran plot, 
which showed that 92.1% of the residues were in the most favored 
region and 0% of the residues were in disallowed regions 
(Ramachandran et al., 1963; Luthy et al., 1992; Colovos and Yeates, 
1993; Laskowski et al., 1993; Shen and Sali, 2006; Figure 1B and 
Supplemental Figures S1 and S2). Structure alignment of STARD9-
MD with KIF1A-MD showed strong structural conservation, with the 
exception of a few extended loops (L7, L11, and L12) in STARD9 
(Pettersen et al., 2004; Figure 1B and Supplemental Figure S3). 
Based on modeling, the STARD9 L12 was predicted to be unstruc-
tured and could potential adopt multiple conformations (one con-
formation is depicted in Figure 1B).
Of interest, we identified a 26–amino acid insertion in L12 that 
contained putative Plk1 polo-box domain (PBD) binding sites (SS 
motifs) and a DSGXXS β-TrCP (SCFβ-TrCP ubiquitin ligase substrate 
adapter) binding motif, indicating that STARD9 may be regulated 
through posttranslational modifications such as phosphorylation 
and ubiquitination (Figure 1C). The L12 insertion, the Plk1-PBD 
binding sites, and the β-TrCP-binding motif were highly conserved 
among all identified STARD9 mammalian orthologues (Figure 1D). 
A survey of the full-length STARD9 protein indicated that the 
DSGXXS β-TrCP-binding motif within the motor domain was the 
only one present within the entire protein, which was also true for all 
STARD9 mammalian orthologues. In addition, the STARD9 DSGILS 
motif matched the canonical DSGXXS β-TrCP-binding motif found 
in β-TrCP substrates such as IκBα, claspin, and Emi1 (Winston et al., 
1999; Margottin-Goguet et al., 2003; Mailand et al., 2006; Frescas 
and Pagano, 2008; Figure 1E). Consistent with a role of the ubiqui-
tin-proteasome system in regulating STARD9 function, previous 
analyses showed that transient overexpression of STARD9-MD led 
to modest increase in PCM fragmentation and multipolar spindle 
formation (Torres et al., 2011).
Cell cycle regulation of STARD9-MD protein levels
To determine whether STARD9-MD protein levels were cell cycle 
regulated by the ubiquitin-proteasome system, we generated 
a doxycycline-inducible localization and affinity purification (LAP = 
enhanced green fluorescent protein [EGFP]–tobacco etch virus–S-
peptide)–tagged STARD9-MD HeLa stable cell line that expresses 
STARD9-MD from a single specific locus within the genome to mon-
itor STARD9-MD protein levels throughout the cell cycle (Torres 
et al., 2009). Indeed, STARD9-MD levels remained high in G1/S and 
mitotic cells in the presence of the proteasome inhibitor MG132 (a 
representative immunoblot is shown in Figure 2A). However, 
STARD9-MD protein levels decreased in mitotic cells in the absence 
of MG132 (a representative immunoblot is shown in Figure 2A). In 
addition, a higher–molecular weight band corresponding to a modi-
fied form of STARD9-MD was apparent in mitotic cells (Figure 2A, 
arrows). To determine whether this modification was specific for mi-
tosis, we synchronized cells in G1/S and released them into the cell 
cycle in the presence of nocodazole. Cells were then harvested ev-
ery 2 h and lysed, and protein samples were analyzed by immunob-
lot analyses (Figure 2B). STARD9-MD was unmodified in G1/S and 
became modified at ∼8 h postrelease during mitotic entry (a repre-
sentative immunoblot is shown in Figure 2B, arrows). To further 
verify that STARD9-MD levels were decreasing during mitosis, cells 
synchronized in early mitosis with nocodazole were released, and 
samples were collected every hour and analyzed by immunoblot-
ting. STARD9-MD protein levels decreased as the cells were re-
leased from early mitosis and exited mitosis and increased again as 
maturation (pericentrin), PCM cohesion (Kizuna), microtubule nucle-
ation and dynamics (Nlp and stathmin), and bipolar spindle assem-
bly (Budde et al., 2001; Casenghi et al., 2003; Barr et al., 2004; 
Hansen et al., 2004; Oshimori et al., 2006; Seki et al., 2008a; Lee 
and Rhee, 2011). The mechanism of Plk1 substrate phosphorylation 
typically involves the binding of its carboxyl-terminal polo-box do-
mains (PBDs) to serine-[phosphoserine/phosphothreonine] (SpS, 
SpT) motifs within substrates before its amino-terminal kinase do-
main can transfer phosphoryl groups onto substrates (Elia et al., 
2003; Lowery et al., 2007).
In addition to phosphorylation, cell cycle progression and cell 
division are largely controlled by two multisubunit ubiquitin ligases, 
anaphase-promoting complex/cyclosome (APC/C) and Skp1/Cul1/
F-box protein–β-TrCP (SCFβ-TrCP), which ubiquitinate and target 
cell cycle regulators for degradation by the proteasome (Cardozo 
and Pagano, 2004; Frescas and Pagano, 2008; Barford, 2011). In the 
case of the SCFβ-TrCP, β-TrCP (an SCF substrate adaptor) binds to 
canonical DSGXXS motifs found in IκBα, claspin, Emi1, and other 
substrates only when both of the motif’s serine residues are phos-
phorylated, which facilitates their ubiquitination and targeting for 
degradation (Winston et al., 1999; Margottin-Goguet et al., 2003; 
Mailand et al., 2006; Frescas and Pagano, 2008). In addition, β-TrCP 
can bind to noncanonical sites, including the DSGXXT motif within 
Bora (Seki et al., 2008a). Although several kinases can phosphory-
late serine/threonine residues within canonical and noncanonical 
β-TrCP recognition motifs, G2/M substrates are predominantly 
phosphorylated by Plk1, including claspin, Bora, and Emi1 
(Margottin-Goguet et al., 2003; Mailand et al., 2006; Seki et al., 
2008a). On the other hand, the APC/C degrades several kinesins 
during mitotic exit, including the kinesin-5 motors Kip1p and Cin8p 
(Saccharomyces cerevisiae), the orphan kinesin motor AtKINUa 
(Arabidopsis thaliana), and kinesin-10 Xkid (Xenopus laevis; Funabiki 
and Murray, 2000; Gordon and Roof, 2001; Hildebrandt and Hoyt, 
2001; Malcos and Cyr, 2011). However, to our knowledge, none of 
the ∼50 human kinesins have been reported to be regulated by the 
SCFβ-TrCP.
Here we applied a multidisciplinary approach to understand the 
cis and trans factors that regulate the protein levels of the STARD9 
motor domain (MD). Molecular modeling of the STARD9-MD identi-
fied a conserved insertion in loop 12, which harbored putative Plk1 
binding sites (SS motifs) and an extended DSGXXSS β-TrCP-binding 
motif. Of interest, this insertion is heavily phosphorylated by mitotic 
kinases that include Plk1, which enables STARD9-MD’s ubiquitina-
tion by the SCFβ-TrCP ubiquitin ligase and its bulk degradation by 
the proteasome. Overexpression of nonphosphorylatable/nonde-
gradable STARD9 motor domain mutants led to spindle assembly 
defects, mitotic arrest, and reduced cell viability. Our analysis of the 
STARD9-MD implies that STARD9 protein levels are regulated 
through posttranslational modifications and that this may be impor-
tant for proper cell division.
RESULTS
The STARD9 motor domain harbors a unique insertion with 
putative regulatory sequences
The large size of STARD9 (∼517 kDa) greatly complicates its expres-
sion and molecular manipulation (Figure 1A). To better understand 
the function of STARD9 in cell division, we sought to characterize its 
kinesin motor domain, which plays a critical role in STARD9’s func-
tion (Torres et al., 2011). To do this, we first modeled the structure of 
the STARD9-MD (amino acids 1–391) based on the KIF1A motor 
domain (with which it shares 48% sequence identity) crystal structure 
(Protein Data Bank [PDB] ID 1IA0) using the homology modeling 
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Consistently, when recombinant GST-STARD9-MD was incubated 
with mitotic extracts it became modified, and the addition of λ 
phosphatase reversed this modification (Figure 3B). To further de-
fine the phosphorylation events that were likely regulating STARD9-
MD stability, we took an unbiased proteomic approach to map the 
STARD9-MD amino acids that were phosphorylated in mitosis. The 
LAP-STARD9-MD HeLa stable cell line was used to express and tan-
dem affinity purify STARD9-MD (Torres et al., 2009). Purifications 
were carried out from G1/S and mitotic cell extracts in the presence 
of phosphatase, protease, deubiquitinase, and proteasome inhibi-
tors to preserve PTMs and prevent protein degradation. Eluates 
from these purifications were separated by gel chromatography, 
and the band corresponding to the phosphorylated form of 
STARD9-MD (present only in the mitotic purification) was excised 
and analyzed by mass spectrometry (Figure 3C). STARD9-MD pep-
tides were then inspected for mass spectra shifts indicative of phos-
phorylation (ST: +79.9663 Da). Surprisingly, we identified 10 phos-
phorylation sites within STARD9-MD, and nine of 10 phosphorylation 
sites mapped to the L12 insertion (Figure 3, D and E). Nine of the 
the cells entered G1 (Figure 2C). Similar to the experiments with 
living cells, recombinant glutathione S-transferase (GST)–STARD9-
MD remained unmodified when incubated with G1/S extracts and 
became modified and degraded when incubated with mitotic ex-
tracts (Figure 2D, arrows). These results indicated that STARD9-MD 
is modified posttranslationally during mitosis and contained the 
minimal sequences required for STARD9-MD’s cell cycle– and prote-
asome-dependent degradation.
Proteomic analysis of the STARD9 motor domain
Because STARD9-MD contained several potential phosphorylation 
sites, we asked whether the modified form of STARD9-MD was due 
to phosphorylation. Extracts were prepared from G1/S or mitotic 
cells expressing STARD9-MD and were subjected to λ phosphatase 
treatment (Figure 3A). Consistent with our previous results, STARD9-
MD was only modified in mitosis and not G1/S (Figure 3A). Of inter-
est, the modified form of STARD9-MD was absent when extracts 
were treated with λ phosphatase (Figure 3A), indicating that the 
modified form of STARD9-MD was due to phosphorylation. 
FIGURE 1: The STARD9 motor domain loop 12 harbors a unique insertion with Plk1 and β-TrCP binding sites.  
(A) Schematic of the STARD9 modular domain composition. (B) Molecular modeling of the STARD9 motor domain using 
the KIF1A motor domain crystal structure (PDB ID 1IA0). Note that loops 7, 11, and 12 are extended. (C) Compared 
with KIF1A, STARD9 contains a 26–amino acid insertion in loop 12 with putative Plk1 polo-box domain–binding motifs 
(SS) and a β-TrCP DSGXXS–binding motif. (D) The 26–amino acid insertion and DSGXXS motif are highly conserved 
among STARD9 mammalian orthologues. (E) Alignment of STARD9, IκBα, claspin, and Emi1 β-TrCP DSGXXS–binding 
motifs and consensus.
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site mutated to an alanine (S304A, S305A, 
S312A, S316A, and S317A, all mutants 
integrated at the same loci within the ge-
nome). In addition, we generated double-
mutant (S312/316A) and triple-mutant 
(S312/316/317A) stable cell lines. Next we 
analyzed the importance of phosphorylation 
for STARD9-MD protein stability. Wild-type 
and serine mutant cell lines were synchro-
nized in G1/S, released, and treated with 
nocodazole for 12 or 20 h and the stability 
of STARD9-MD monitored by immunoblot 
analysis. Whereas wild type, S304A, and 
S316A were degraded by 20 h, S305A, 
S312A, S317A, the double mutant, and the 
triple mutant remained stabilized (Figure 4A). 
Consistently, protein half-life experiments 
(in which cells were synchronized in early mi-
tosis with nocodazole and released into the 
presence of cycloheximide, with samples 
collected every hour and analyzed by immu-
noblotting) showed that S305A, S312A, and 
S317A STARD9-MD mutants had a longer 
half-life than wild-type STARD9-MD (Figure 
4B). These results indicated that the phos-
phorylation of S305, S312, and S317 played 
critical roles in the degradation of STARD9-
MD. β-TrCP is also known to bind and ubiq-
uitinate proteins with a modified consensus 
that includes one or two additional amino 
acids between the two phosphoserines—
example p105 (DpSGVETpS) and CDC25A 
(DpSGFCLDpS; Busino et al., 2003; Lang 
et al., 2003). Because S312 and S317 were 
phosphorylated and played a role in the 
degradation of STARD9-MD, we asked 
whether the β-TrCP substrate-binding site 
could accommodate the extended consen-
sus STARD9-MD phosphodegron (DpSGIL-
SpS). Indeed, similar to a previous analysis 
of p105 and CDC25A, molecular modeling 
indicated that the β-TrCP substrate-binding site within the WD40 
domain accommodated the DpSGILSpS peptide, with the extended 
hydrophobic part of the peptide moving deeper into the pocket 
(Kanarek et al., 2010; Figure 4C and Supplemental Figure S5).
Phosphorylation of STARD9-MD by Plk1 is required 
for its degradation
Given that STARD9-MD harbored Plkl binding sites that were 
phosphorylated in mitosis (S304pS305 and S316pS317; Figure 3, 
C–E), we asked whether Plk1 bound to STARD9-MD and was able 
to phosphorylate it. LAP-tagged STARD9-MD wild type or S317A 
was immunoprecipitated from G1/S or mitotic cells, and eluates 
were immunoblotted for Plk1. Indeed, endogenous Plk1 bound 
preferentially to the mitotic phosphorylated STARD9-MD in com-
parison to the G1/S nonphosphorylated STARD9-MD (Figure 5A). 
Furthermore, endogenous Plk1 was unable to bind the nonde-
gradable/nonphosphorylated S317A STARD9-MD mutant (Figure 
5A). Consistently, overexpressed hemagglutinin (HA)-Plk1-KD 
(kinase-dead form, binds to substrates but does not phosphorylate 
them) coimmunoprecipitated with STARD9-MD from mitotic cells 
(Supplemental Figure S6). The interaction between Plk1 and 
phosphorylation sites were on serines (serines 304, 305, 307, 312, 
316, 317, 319, 328, and 332) and one was on threonine 321, with 
serines 305 and 317 being the most abundantly phosphorylated 
(Figure 3, D and E, and Supplemental Figure S4). Of interest, serines 
312 and 316 within the DSGXXS motif were phosphorylated, indi-
cating that a DpSGXXpS phosphodegron could be regulating 
STARD9-MD protein levels (Figure 3, D and E, and Supplemental 
Figure S4). In addition, two putative Plk1-PBD binding sites, 
S316:S317 (SpSP canonical) and S304:S305 (SpSV noncanonical), 
were also phosphorylated (Figure 3, D and E, and Supplemental 
Figure S4).
Phosphorylation of the STARD9-MD L12 insertion regulates 
STARD9-MD protein stability
Owing to the large number of phosphorylation sites within the 
STARD9-MD, we focused on serine residues that spanned the puta-
tive Plk1-PBD SpS binding sites (S304:S305 and S316:S317) and the 
β-TrCP-binding DpSGXXpS motif (S312 and S316) that were found 
phosphorylated in mitosis (Figure 3, C–E, and Supplemental Figure 
S4). To analyze the importance of phosphorylating these serines, we 
generated LAP-tagged STARD9-MD stable cell lines that had each 
FIGURE 2: The STARD9 motor domain is modified and degraded in mitosis. (A) The LAP-tagged 
STARD9-MD cell line was double thymidine blocked (DTB; 0 h) and released into the cell cycle in 
the presence of nocodazole (NOC; 20 h) ± MG132. Extracts were immunoblotted with indicated 
antibodies, and the levels of STARD9-MD were quantified (arbitrary units [AU]) for each 
condition. Data represent the average ± SD of three independent experiments. (B) Same as in A, 
except that no MG132 was added, and protein extracts were prepared at the indicated time 
points and analyzed by immunoblotting with the indicated antibodies. The ratio of modified/
unmodified STARD9-MD was quantified for each condition as indicated. Data represent the 
average ± SD of three independent experiments. (C) The LAP-tagged STARD9-MD cell line was 
synchronized in early mitosis with nocodazole for 16 h and released into fresh medium. Samples 
were collected each hour and analyzed by immunoblotting with the indicated antibodies. Plk1 
was used as a mitotic marker (degraded in early G1 phase). Note that STARD9-MD protein 
levels decreased during mitosis when Plk1 was present. (D) Recombinant STARD9-MD (GST-MD) 
was incubated with G1/S or mitotic extracts, and the appearance of the modified form of 
GST-MD was monitored by immunoblot analysis.
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lated (incubated with mitotic extracts) GST-STARD9-MD compared 
with nonphosphorylated (not incubated with mitotic extracts) 
STARD9-MD and control GST (Supplemental Figure S6). These 
phosphorylated STARD9-MD was also assessed by in vitro binding 
assays in which in vitro translated HA-Plk1 or HA-Plk1-KD both 
immunoprecipitated preferentially with recombinant phosphory-
FIGURE 3: Proteomic analysis of the STARD9 motor domain. (A) STARD9-MD was purified from G1/S (thymidine, 0 h) or 
mitotic (nocodazole, 12 h) extracts and either treated or not treated with λ phosphatase and analyzed by immunoblot 
analysis with the indicated antibodies. (B) Recombinant GST-STARD9-MD was incubated with mitotic extracts in the 
presence or absence of λ phosphatase, and the appearance of the modified form of GST-STARD9-MD was monitored by 
immunoblot analysis. (C) Tandem affinity purification of LAP-STARD9-MD from G1/S (thymidine, 0 h) or mitotic 
(nocodazole, 12 h) HeLa cell extracts. Eluates were separated by SDS–PAGE, and protein bands were visualized by silver 
staining the gel. Immunoblot analysis of these samples was used to verify the identity of STARD9-MD throughout the 
purification process. The phosphorylated STARD9-MD band present only in mitotic purifications was excised and 
analyzed by mass spectrometry to map phosphorylation sites. (D) Identified STARD9-MD phosphorylation sites are 
highlighted with arrows and their amino acid position. Red amino acids were phosphorylated, and yellow amino acids 
were found to be the most abundantly phosphorylated. (E) The phosphorylation sites were mapped onto the STARD9-
MD modeled structure. Nine of 10 phosphorylation sites mapped to the 26–amino acid insertion in the flexible loop 12, 
and one was outside this region.
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the LAP-tagged STARD9-MD cell line with 
HA-Plk1 or HA-Plk1-KD overexpression 
vectors and monitored the stability of 
STARD9-MD by immunoblot analysis dur-
ing release from early mitosis. Overexpres-
sion of HA-Plk1 led to a decrease in 
STARD9-MD protein levels, whereas over-
expression of HA-Plk1-KD (binds and inhib-
its phosphorylation of substrates) led to a 
stabilization of STARD9-MD (Figure 5E). On 
the other hand, the depletion of Plk1 
(Figure 5D) or overexpression of Plk1 or 
Plk1-KD (Figure 5E) did not change the 
protein levels of S312A STARD9-MD mu-
tant, indicating that phosphorylation of 
S312 played an important role in the mod-
ulation of STARD9-MD protein levels. To-
gether these results indicated that Plk1 was 
able to bind to phosphorylated STARD9-
MD and was responsible for phosphorylat-
ing it at serine 312 and that this phosphory-
lation event was critical for regulating 
STARD9-MD protein stability.
β-TrCP binds to STARD9-MD and is 
required for its degradation
The binding of β-TrCP to canonical 
(DpSG(2X)pS) and extended phosphode-
grons (DpSG(3X)pS or DpSG(4X)pS) is critical 
for SCFβ-TrCP substrate ubiquitination and 
degradation (Margottin et al., 1998; Busino 
et al., 2003; Lang et al., 2003). Our mass 
spectrometry and mutagenesis data indi-
cated that serines 312 and 317 within the 
STARD9-MD DpSGXXSpS motif were phos-
phorylated in mitosis and required for 
STARD9-MD degradation. Thus we asked 
whether β-TrCP was able to interact with 
STARD9-MD, by performing coimmunoprecipitation assays. In 
these assays, phosphorylated or nonphosphorylated GST-STARD9-
MD was obtained after incubation with or without M-phase–arrested 
cell extracts (Figure 6A). The two forms of GST-STARD9-MD were 
incubated with HA-β-TrCP or HA-β-TrCPΔF (dominant-negative mu-
tant is able to bind substrates but not ubiquitinate them) and im-
munoprecipitated. The association of HA-β-TrCP or HA-β-TrCPΔF 
with STARD9-MD was then analyzed by immunoblot analysis. HA-β-
TrCP and HA-β-TrCPΔF both immunoprecipitated preferentially with 
phosphorylated GST-STARD9-MD compared with nonphosphory-
lated GST-STARD9-MD and control GST (Figure 6B and Supplemen-
tal Figure S7). Conversely, β-TrCP did not immunoprecipitate with 
the nonphosphorylatable/nondegradable S317A STARD9-MD mu-
tant (Figure 6, C and D). To determine the importance of β-TrCP in 
regulating the levels of STARD9-MD in mitosis, we overexpressed 
HA-β-TrCP or HA-β-TrCPΔF in cells and analyzed their effect on 
STARD9-MD protein levels during their release from nocodazole. 
Overexpression of HA-β-TrCP led to a slight reduction in the levels 
of STARD9-MD compared with control (CTRL) transfections during 
mitosis (Figure 6E). In contrast, overexpression of HA-β-TrCPΔF led 
to the stabilization of STARD9-MD in mitosis (Figure 6E). Accord-
ingly, siRNA-mediated RNA interference targeting endogenous β-
TrCP resulted in the stabilization of STARD9-MD (Figure 6, F and G) 
during mitosis. These results indicated that β-TrCP bound to 
results indicated that Plk1 was binding to phosphorylated STARD9-
MD. Next we asked whether Plk1 could directly phosphorylate 
STARD9-MD. In vitro phosphorylation assays were carried out with 
recombinant wild type or serine-to-alanine STARD9-MD mutants 
and [γ-32P]ATP in the presence or absence of recombinant Plk1. 
The transfer of the [γ-32P]phosphate group onto STARD9-MD was 
then monitored by Western blot and radiometric analyses. In this 
assay, Plk1 was able to phosphorylate wild type and S304A, S305A, 
S316A, and S317A single mutants, although S304A, S305A, and 
S316A had a minimal reduction in phosphorylation compared with 
wild type. However, only minimal phosphorylation was observed 
with the S312A single mutant and the double and triple mutants 
that also contained the S312A mutation (Figure 5B). These results 
indicated that Plk1 was phosphorylating S312 and that phosphory-
lation at other serines was likely due to other mitotic kinases. Fi-
nally, we asked whether Plk1 regulated STARD9-MD protein levels 
in vivo. Treatment of cells with the Plk1 inhibitor BI2536 or 
GSK461364 led to the stabilization of STARD9-MD in mitosis (a 
representative immunoblot is shown in Figure 5C). Consistently, 
depletion of Plk1 in LAP-tagged STARD9-MD wild-type cells, 
which had been synchronized in early mitosis with nocodazole and 
released into the cell cycle, inhibited the degradation of STARD9-
MD (Figure 5D). To assess further whether Plk1 phosphorylation 
was regulating the degradation of STARD9-MD, we transfected 
FIGURE 4: Phosphorylation at serines 305, 312, and 317 regulates STARD9-MD protein stability. 
(A) HeLa stable cell lines expressing STARD9-MD wild type, serine-to-alanine single mutants 
(S304A, S305A, S312A, S316A, and S317A), double mutants (S312/316A), and triple mutants 
(S312/316/317) were arrested in G1/S and released into the cell cycle in the presence of 
nocodazole for 12 or 20 h. Extracts from these time points were immunoblotted to monitor the 
levels of STARD9-MD and tubulin. (B) HeLa stable cell lines expressing STARD9-MD wild type 
and serine-to-alanine single mutants (S305A, S312A, and S317A) were arrested in early mitosis 
with nocodazole for 16 h and treated with cycloheximide during the release. Samples were 
collected each hour and analyzed by immunoblotting to monitor the levels of STARD9-MD.  
(C) Molecular modeling of the interaction between β-TrCP and the STARD9-MD extended 
phosphodegron (DpSGILSpS) peptide.
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tive control. Together these results indicated that β-TrCP preferen-
tially binds to phosphorylated STARD9-MD and that STARD9-MD is 
an SCFβ-TrCP substrate.
Increased STARD9-MD protein levels lead to PCM 
fragmentation and spindle assembly defects
To analyze the consequences of accumulating STARD9-MD in mito-
sis, we used LAP-tagged STARD9-MD wild-type and serine-to-ala-
nine mutant stable cell lines (expressing STARD9-MD from the same 
single chromosomal loci) to overexpress wild type and nonphos-
phorylatable/nondegradable STARD9-MD mutants and analyzed 
their mitotic defects by immunofluorescence microscopy. Consistent 
with our previous results, overexpressed STARD9-MD localized to 
the spindle poles and, to a lesser extent, the spindle microtubules 
phosphorylated STARD9-MD and that SCFβ-TrCP was involved in 
the degradation of STARD9-MD in a cell cycle–dependent manner. 
To further test this, we asked whether STARD9-MD was an SCFβ-
TrCP substrate in an in vitro reconstituted ubiquitination assay (Laney 
and Hochstrasser, 2011). For these assays, recombinant GST-
STARD9-MD was incubated with an ATP-regeneration system, ubiq-
uitin, an E1 ubiquitin- activating enzyme, an E2 ubiquitin-conjugating 
enzyme, and the SCFβ-TrCP (recombinant Skp1, ±Cul1, ±β-TrCP and 
Roc1). Reactions were incubated at 30°C for 120 min, and ubiquitina-
tion products were resolved by SDS–PAGE and immunoblotted with 
anti-ubiquitin and anti-GST antibodies. We observed polyubiquitin 
STARD9-MD as a ladder of increasing molecular weight bands that 
was largely reduced in the absence of Cul1 or β-TrCP (Figure 6H). In 
these assays, Emi1 served as a positive control and GFP as a nega-
FIGURE 5: Plk1 binds to STARD9-MD, phosphorylates it at serine 312, and regulates its degradation.  
(A) Immunoprecipitation of LAP-tagged STARD9-MD wild type and S317A mutant from G1/S or mitotic extracts. Eluates 
were immunoblotted for the indicated proteins. Note that Plk1 only coimmunoprecipitates with mitotic phosphorylated 
wild-type STARD9-MD and not the nonphosphorylated S317A STARD9-MD mutant. NI indicates the noninduced control. 
(B) Plk1 phosphorylates STARD9-MD at serine 312. In vitro phosphorylation assays were carried out with recombinant 
wild type or serine-to-alanine mutant STARD9-MD. The transfer of the [γ-32P]phosphate group onto STARD9-MD was 
monitored by Western blot and radiometric analyses. (C) Plk1 regulates STARD9-MD protein levels in vivo. The 
LAP-tagged STARD9-MD cell line was synchronized in G1/S and released into nocodazole-containing media in the 
presence or absence of BI2536 or GSK461364 Plk1 inhibitors, mitotic cells were harvested 20 h postrelease, protein 
extracts were analyzed by immunoblotting for the indicated proteins, and the levels of STARD9-MD were quantified for 
each condition. Data represent the average ± SD of three independent experiments. (D) siRNA knockdown of 
endogenous Plk1 protein in LAP-tagged STARD9-MD wild-type and S312A mutant cell lines. Cells were synchronized in 
early mitosis with nocodazole for 16 h and released, and samples were collected at the indicated time points and 
immunoblotted with the indicated antibodies. CTRL indicates control siRNA. (E) The LAP-tagged STARD9-MD wild-type 
and S312A cell lines were transfected with HA-Plk1 or HA-Plk1-KD overexpression vectors, cells were arrested in mitosis 
with nocodazole for 16 h and released into fresh medium, and extracts were prepared at the indicated time points and 
immunoblotted with the indicated antibodies.
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whether these factors protect STARD9-MD from posttranslational 
modifications.
Structural modeling of kinesin-3 family members indicates that 
L12 makes contact with the microtubule backbone. Of interest, 
STARD9 appears to be the only kinesin with a 26–amino acid inser-
tion in L12, and within the context of our STARD9-MD studies, this 
insertion is heavily phosphorylated in mitosis. In addition to regulat-
ing STARD9-MD protein stability, phosphorylation could also affect 
the ability of STARD9-MD to interact with microtubules and/or hy-
drolyze ATP. Thus further structure–function analyses are necessary 
to fully understand how posttranslational modifications influence 
STARD9-MD’s activity. Although Plk1 was shown to be important for 
phosphorylating STARD9-MD at serine 312, the identity of the 
kinase(s) required for phosphorylating other critical serines (305 and 
317) that regulate STARD9-MD protein levels is unknown, as well as 
that of the kinase(s) that phosphorylate STARD9-MD at other serines 
(304, 307, 316, 319, 328, and 332) and threonine 321. Thus it will be 
important to identify the mitotic kinase(s) responsible for these 
phosphorylating events.
The composition of mammalian centrosomes and spindle as-
sembly factors is more complex than that for lower eukaryotes. 
Consistently, factors critical for mammalian spindle assembly such 
as Bora, Kizuna, and STARD9 are not evolutionarily conserved 
(Oshimori et al., 2006; Seki et al., 2008b; Torres et al., 2011). 
Mammalian cells have evolved specialized mechanisms to deal 
with an open mitosis and the stresses of forming a productive mi-
totic spindle. Not surprisingly, mammalian cells tightly regulate the 
protein levels of critical factors necessary for cell cycle progression. 
It is largely unknown why perturbing the levels of STARD9 has del-
eterious consequences (Torres et al., 2011). One possibility is that 
STARD9 is in equilibrium with other PCM scaffolding factors, and 
the lack of complex formation in the absence of STARD9 or pertur-
bation of these complexes through competition by overexpressing 
STARD9-MD may lead to complex inactivation. Further character-
ization of the interactions that STARD9 undergoes at the centro-
some should provide insight into its mechanism of action.
MATERIALS AND METHODS
Cell culture and cell cycle synchronization
HeLa and HeLa Flp-In T-REx LAP-tagged stable cell lines were grown 
as described previously (Senese et al., 2014). Cells were induced to 
express the indicated proteins by 0.1 μg/ml doxycycline (Sigma-
Aldrich, St. Louis, MO) and synchronized in G1/S by treatment with 
2 mM thymidine (Sigma-Aldrich) for 18-h. Alternatively, cells were 
synchronized at G2/M by a thymidine-nocodazole arrest (18 h in 
2 mM thymidine-containing medium and then release into 330 nM 
nocodazole [Sigma-Aldrich]-containing medium for 12 h). To obtain 
synchronized cells in mitosis, cells were treated with 300 nM no-
codazole (Sigma-Aldrich) for 12–20 h as indicated and collected by 
mitotic shake-off. To analyze the progression from mitosis to G1, 
after synchronization in early mitosis by nocodazole for 16 h, cells 
were collected by mitotic shake off, washed, and released into fresh 
medium. The proteasome inhibitor MG132 (Calbiochem, Billerica, 
MA) was added to mitotic-arrested cells at 10 μM 4 h before har-
vesting cells. For in vivo Plk1 inhibition, cells were incubated 
200 nM GSK461364 (GlaxoSmithKline, Philadelphia, PA) or BI22536 
(Selleckchem, Houston, TX). To determine the half-life of proteins, 
doxycycline-induced and mitotic- synchronized HeLa cells were re-
leased into the cell cycle and treated with 100 μg/ml cycloheximide 
(Sigma-Aldrich), and at the indicated time points, whole-cell extracts 
were prepared and subjected to immunoblot analysis with the indi-
cated antibodies.
(Torres et al., 2011; Figure 7A). However, the nonphosphorylatable/
nondegradable S305A, S312A, and S317A mutants accumulated to 
very high levels at the spindle poles and spindle, consistent with our 
immunoblot analyses showing their stabilization in mitosis 
(Figure 7A). As a control, STARD9-MD with the S316A mutation that 
did not block STARD9-MD degradation remained at similar low lev-
els as wild-type STARD9-MD (Figure 7A). Similarly, measurements of 
the total fluorescence intensity of LAP-STARD9-MD at the centro-
some indicated that STARD9-MD protein levels were markedly 
increased in the S305A, S312A, and S317A mutants, whereas wild-
type STARD9-MD and the degradation-competent S316A mutant 
remained low (Figure 7B). Also consistent with previous results, 
overexpression of STARD9-MD led to a modest but reproducible 
increase in the percentage of cells with spindle defects (PCM 
fragmentation and multipolar spindles): ∼18% compared with ∼8% 
control (Torres et al., 2011; Figure 7, A and C). A similar effect was 
also seen with the degradation-competent S316A mutant (Figure 7, 
A and C). Of interest, overexpression of the nonphosphorylatable/
nondegradable S305A, S312A, and S317A mutants led to signifi-
cant increase in the percentage of cells with spindle assembly de-
fects, ∼25–30% (Figure 7, A and C). Consistently, live-cell time-lapse 
microscopy of nonphosphorylatable/nondegradable mutants like 
S317A indicated that overexpressing these mutants led to an arrest 
in mitosis, followed by apoptotic cell death (Figure 7D and Supple-
mental Movies S1–S4). These data indicated that posttranslational 
modification of STARD9-MD by Plk1 (phosphorylation) and SCFβ-
TrCP (ubiquitination) was critical for controlling the levels of STARD9-
MD at the centrosome during mitosis and that accumulation of 
STARD9-MD led to spindle assembly and cell division defects.
DISCUSSION
Mitotic kinases such as Plk1, Nek, Cdk1, and Aurora A/B are known 
to phosphorylate mitotic kinesins and thereby modulate their ac-
tivities and functions during mitosis (Andrews et al., 2004; Cahu 
et al., 2008; Jang et al., 2009; Bertran et al., 2011; Sdelci et al., 
2011). An alternative mode of regulating kinesin activity/function is 
through protein degradation. The APC/C ubiquitin ligase targets 
numerous mitotic kinesins for degradation as the cells transition 
into anaphase, and degradation of these kinesins is critical for com-
pletion of mitosis (Funabiki and Murray, 2000; Gordon and Roof, 
2001; Hildebrandt and Hoyt, 2001; Malcos and Cyr, 2011). On the 
other hand, the SCFβ-TrCP, another major ubiquitin ligase respon-
sible for driving the cell cycle, degrades cell cycle regulators such 
as Emi1 and Bora in early mitosis (Margottin-Goguet et al., 2003; 
Hansen et al., 2004; Seki et al., 2008b). However, the SCFβ-TrCP 
had not been demonstrated to degrade kinesins. Here we deter-
mined that the motor domain of the STARD9 mitotic kinesin is a 
substrate of the SCFβ-TrCP and a pool of STARD9-MD is degraded 
in mitosis. Our data suggest that in vivo the protein levels of full-
length STARD9 could be regulated through Plk1 phosphorylation, 
SCFβ-TrCP ubiquitination, and proteasome-dependent degrada-
tion. Of interest, the STARD9-MD contained a highly conserved β-
TrCP- binding motif, harbored putative Plk1 binding sites, and was 
phosphorylated by Plk1 and ubiquitinated by the SCFβ-TrCP dur-
ing mitosis (Figures 1–6). In addition, a pool was degraded in a 
proteasome-dependent manner, and the remaining STARD9-MD 
remained localized to the centrosomes and mitotic spindle (Figure 
7). The interactions that STARD9-MD maintains at the centrosome 
are unknown; it is likely, however, that its association with centro-
somal components could protect it from Plk1 phosphorylation and/
or SCFβ-TrCP ubiquitination. Thus it will be important to identify 
the full complement of STARD9-MD interactors and determine 
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FIGURE 6: β-TrCP binds to STARD9-MD and regulates its degradation. (A) GST-STARD9-MD (GST-MD) was incubated 
with or without mitotic extracts and became phosphorylated in mitotic extracts. (B) β-TrCP binds to STARD9-MD in 
vitro. GST-STARD9-MD was incubated with HA-β-TrCP for 1 h and washed, and the binding was monitored by 
immunoblot analysis. (C) GST-STARD9-MD (GST-MD) or the mutant GST-STARD9-MD S317A (GST-MD S317A) was 
incubated with or without mitotic extracts, and only GST-MD became phosphorylated in mitotic extracts. (D) GST-
STARD9-MD or GST-STARD9-MD S317A was incubated with HA-β -TrCP for 1 h and washed, and the binding was 
monitored by immunoblot analysis. (E) The LAP-tagged STARD9-MD wild-type cell line was transfected with HA-β-TrCP 
or HA-β-TrCPΔF overexpression vectors, synchronized in mitosis with nocodazole for 16 h, and released into the cell 
cycle, and the stability of STARD9-MD was monitored by immunoblot analysis. (F) The knockdown efficiency of siRNA 
targeting β-TrCP expression was determined by RT (reverse transcription)-qPCR. Data represent the average ± SD of 
three independent experiments. (G) The LAP-tagged STARD9-MD wild-type cell line was transfected with control siRNA 
or siRNA targeting β-TrCP, synchronized in mitosis with nocodazole for 16 h, and released into the cell cycle, and the 
stability of STARD9-MD was monitored by immunoblot analysis. (H) STARD9-MD is a substrate of the SCFβ-TrCP 
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pGEX4T1-NT-EMI1 vector was used to express recombinant 
Emi1, and pDEST24-GST-GFP was used as an additional control. 
STARD9-MD point mutants were generated using the 
QuikChange Lightning Site-Directed Mutagenesis Kit (Agilent 
Technologies, La Jolla, CA) with primers carrying the desired 
mutations. All primers were purchased from Fisher Scientific 
(Pittsburgh, PA).
Plasmids, mutagenesis, and generation of stable cell lines
For STARD9-MD expression, the first 387 amino acids of STARD9 
were fused to the C-terminus of either GST (pGEX-6P vector) 
or EGFP (pGLAP1 vector; Torres et al., 2009). For expression 
in human cells, the pCS2-HA-β-TrCP, pCS2-HA-β-TrCPΔF, 
pCS2-HA-CUL1, pCS2-HA-PLK1, pCS2-HA-PLK1-K82R, and 
pCS2-HA-KATNA1 (control) vectors were used. In addition, the 
ubiquitin ligase. In vitro ubiquitination reactions were carried out with recombinant GST-STARD9-MD, GST-Emi1, or 
GST-GFP and with or without ubiquitin, E1, E2, Roc1, Skp1, Cul1, β-TrCP, and mitotic extracts. Products were resolved 
by SDS–PAGE and immunoblotted with anti-ubiquitin and anti-GST antibodies. Higher-molecular-weight bands are 
indicative of ubiquitination.
FIGURE 7: Increased levels of STARD9-MD lead to spindle assembly and cell division defects. (A) STARD9-MD wild-type 
and serine-to-alanine mutant stable cell lines were induced to express these proteins. Twenty hours postinduction, cells 
were fixed and stained for DNA, α-tubulin, and STARD9-MD and imaged by fluorescence microscopy. Bar, 5 μm.  
(B) Quantification of the fluorescence intensity signal from STARD9-MD wild-type and serine-to-alanine mutant proteins 
within a 3-μm radius surrounding the centrosome/spindle pole. Data represent the average ± SD of three independent 
experiments, 20 cells counted for each. *p < 0.05, **p < 0.0005. (C) The percentage of cells with spindle defects was 
quantified. Data represent the average ± SD of three independent experiments, 100 cells counted for each. *p < 0.05, 
**p < 0.005, ***p < 0.0005. (D) Live-cell time-lapse microscopy of STARD9-MD wild type and S317A mutant. Top, 
bright-field (BF) snapshots, and bottom, fluorescence (FL), of STARD-MD localization at the indicated time points in 
minutes. See Supplemental Movies S1–S4.
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1 mM DTT), and protein was eluted by adding elution buffer (50 mM 
Tris-HCl, pH 7.4, 200 mM NaCl, 2.5 mM EDTA, 2.5 mM EGTA, 2 mM 
MgCl2, 0.02% Triton X-100, 10% glycerol, 0.25 mM ATP, 1 mM DTT, 
50 mM glutathione). The purified protein was concentrated using an 
Amicon Ultra 30K concentrator and dialyzed in dialysis buffer (50 mM 
Tris-HCl, pH 7.4, 200 mM NaCl, 2.5 mM EDTA, 2.5 mM EGTA, 2 mM 
MgCl2, 0.02% Triton X-100, 10% glycerol, 0.25 mM ATP, 1 mM DTT) 
overnight. The protein was concentrated again, aliquoted, and flash-
frozen in liquid nitrogen and stored at −80°C.
Phosphorylation assays
Extracts of HeLa cells synchronized in G1/S by a thymidine treatment 
or in mitosis by a thymidine release into nocodazole treatment were 
prepared as described (Seki et al., 2008a), aliquoted at a concentra-
tion of 10 μg/μl, flash-frozen in liquid nitrogen, and stored at −80°C. 
For each reaction on ice, 10 μl of extracts was supplemented with 
1 μl of ATP regeneration solution (Enzo Life Science, Farmingdale, 
NY), and 1 μg of bacterial STARD9-MD protein was added. Reac-
tions were shifted to 30°C and stopped at the indicated times by the 
addition of sample buffer. Samples were resolved by a 4–20% gradi-
ent Tris gel (Bio-Rad) with MOPS running buffer.
Phosphatase assays
Cells were lysed in LAP300 lysis buffer (50 mM HEPES, pH 7.4, 
300 mM KCl, 1 mM EGTA, 1 mM MgCl2, 10% glycerol) plus 0.3% 
NP-40, 0.5 mM DTT, 10 μM MG132, 20 mM NEM, and protease 
inhibitor cocktail (Thermo Scientific), and 1200 U of λ phosphatase 
(New England BioLabs, Ipswich, MA) was added to 50 μg of pro-
tein lysates. The reaction was carried out at 30°C for 1 h and 
stopped by the addition of sample buffer.
Ubiquitination reactions
A 10-μg amount of recombinant GST-tagged STARD9-MD, EMI1, or 
GFP was bound to magnetic glutathione beads (Thermo Scientific) 
and incubated with mitotic HeLa cell extracts along with an ATP re-
generation system (Enzo Life Sciences) for 3 h at 30°C. After 3 h, a 
master mix containing all the ubiquitination components (ubiquitin 
[Enzo Life Sciences], ROC1, E1, E2, Skp1, with or without β-TrCP, with 
or without CUL1, in a buffer containing 20 mM HEPES, 5 mM NaCl, 
5 mM MgCl2, DTT, MG132, and protease and phosphatase inhibitor 
cocktail (Thermo Scientific) and ATP regeneration system was added 
to the tubes and further incubated for 90 min at 30°C. The beads 
were then washed four times with a wash buffer containing 20 mM 
HEPES, 100 mM NaCl, 5 mM MgCl2, 15 mM imidazole, 0.5% Triton-X, 
β-mercaptoethanol, DTT, MG132, and a protease and phosphatase 
inhibitor cocktail. The beads were then boiled in 2× Laemmli sample 
buffer (Bio-Rad) and loaded onto a 4–12% TGX gel (Bio-Rad), fol-
lowed by Western transfer. The blots were subsequently probed with 
anti-GST (Abcam, Cambridge, MA) and anti-ubiquitin (Enzo Life 
Sciences) antibodies.
Homology modeling of the STARD9 motor domain structure
The STARD9 motor domain structure was modeled using the mod-
eller-9v8 program by satisfying spatial constraints (Sali and Blundell, 
1993). Briefly, the STARD9 sequence was blasted against the PDB 
database in the National Center for Biotechnology Information server 
to retrieve homologous sequences with solved three-dimensional 
structures. KIF1A (PDB ID 1IA0) was identified as the best template, 
which shares 48% sequence identity with the STARD9 kinesin motor. 
The initial sequence alignment was performed using the automodel 
routine as part of the automated modeling procedures. One hundred 
structures were generated by varying the initial conformation and 
were subsequently refined using simulated annealing and molecular 
Primer sequences were as follows:
S304A STARD9-MD
Forward: 5′-ctgccagagcctcaacgcctcagtcagcaatggt-3′
Reverse: 5′-accattgctgactgaggcgttgaggctctggcag-3′
S305A STARD9-MD
Forward: 5′-cagagcctcaacagcgcagtcagcaatggtg-3′
Reverse: 5′-caccattgctgactgcgctgttgaggctctg-3′
S312A STARD9-MD
Forward: 5′-tcagcaatggtggtgacgctgggatccttagctctc-3′
Reverse: 5′-gagagctaaggatcccagcgtcaccaccattgctga-3′
S316A STARD9-MD
Forward: 5′-gtggtgacagtgggatccttgcctctccttctggg-3′
Reverse: 5′-cccagaaggagaggcaaggatcccactgtcaccac-3′
DM STARD9-MD
Forward: 5′-gtggtgacgctgggatccttgcctctccttctgggaccagc-3′
Reverse: 5′-gctggtcccagaaggagaggcaaggatcccagcgtcaccac-3′
S317A STARD9-MD
Forward: 5′-gtgggatccttagcgctccttctgggacc-3′
Reverse: 5′-ggtcccagaaggagcgctaaggatcccac-3′
TM STARD9-MD
Forward: 5′-ctgggatccttgccgctccttctgggacc-3′
Reverse: 5′-ggtcccagaaggagcggcaaggatcccag-3′
The pGLAP1-STARD9-MD wild-type and mutant vectors were 
used to generate doxycycline-inducible HeLa Flp-In T-REx LAP-
STARD9-MD wild-type and mutant stable cell lines that express 
these fusion proteins from a specific single loci within the genome 
as described (Torres et al., 2009).
Immunoprecipitation and LAP purification
Indicated cell lines or HeLa cells transfected with indicated vectors 
were arrested at the indicated cell cycle phases. Whole-cell extracts 
were prepared in LAP300 lysis buffer (50 mM 4-(2-hydroxyethyl)-
1-piperazineethanesulfonic acid [HEPES], pH 7.4, 300 mM KCl, 1 mM 
ethylene glycol tetraacetic acid [EGTA], 1 mM MgCl2, 10% glycerol) 
plus 0.3% NP-40, 0.5 mM dithiothreitol (DTT), 10 μM MG132, 20 mM 
N-ethylmaleimide (NEM), and protease and phosphatase inhibitor 
cocktail (Thermo Scientific, Waltham, MA). Immunoprecipitations 
were performed as previously described (Torres et al., 2009). Samples 
were resolved in a 4–20% gradient Tris gel (Bio-Rad, Philadelphia, PA) 
with 3-(N-morpholino)propanesulfonic acid (MOPS) running buffer, 
transferred to polyvinylidene fluoride membrane, and immunoblot-
ted with indicated antibodies. Similarly LAP-tag tandem affinity purifi-
cations were performed as described in (Torres et al., 2009).
Recombinant protein expression and purification
Recombinant GST-fusion proteins (STARD9-MD wild type and mu-
tants) were induced in Escherichia coli BL-21 pLyse-E with 300 μM 
isopropyl-β-d-thiogalactoside for 6 h at 30°C. After centrifugation, 
cells were lysed with lysis buffer (50 mM Tris-HCl, pH 7.4, 300 mM 
NaCl, 2.5 mM EDTA, 2.5 mM EGTA, 2 mM MgCl2, 0.02% Triton 
X-100, 0.25 mM ATP, 1 mM DTT, and protease inhibitors). The lysate 
was passed through a microfluidizer and clarified by centrifugation at 
15,000 rpm for 30 min. The binding to glutathione Sepharose beads 
(GE Healthcare) was performed for 2 h at 4°C. The pellet was washed 
in wash buffer (50 mM Tris-HCl, pH 7.4, 200 mM NaCl, 2.5 mM EDTA, 
2.5 mM EGTA, 2 mM MgCl2, 0.02% Triton X-100, 0.25 mM ATP, 
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mass spectrometer as described (Vanderwerf et al., 2009). Identified 
phosphorylation sites are indicated in Supplemental Figure S4.
Antibodies
Immunofluorescence, immunoblotting, and immunoprecipitations 
were carried out using antibodies against the following: GFP and 
Securin (Abcam), phospho-S10-H3 (Millipore, Billerica, MA), glycer-
aldehyde-3-phosphate dehydrogenase (GeneTex, Irvine, CA), 
ubiquitin (Enzo Life Sciences), GST (Abcam), CDC27 (GeneTex), 
Wee1 (GeneTex), S-tag (GeneTex), α-tubulin (Serotec, Raleigh, 
NC), HA (Cell Signaling, Danvers, MA), cyclin A and cyclin B (Santa 
Cruz Biotechnology, Dallas, TX), and Plk1 (Abcam). Secondary anti-
bodies conjugated to fluorescein isothiocyanate (FITC) and Cy3 
were from Jackson ImmunoResearch (Affinipure, West Grove, PA).
siRNA-based gene expression knockdown
Cells were transfected with 50 nM Dharmacon ON-TARGETplus 
SMARTpool siRNA targeting PLK1 (L-003290-00) or β-TRCP (L-
003463-00) using Lipofectamine 3000 (Invitrogen, Grand Island, NY) 
according to the manufacturer’s protocol. At 48 h posttransfection, 
cells were collected, and whole extracts were subjected to immuno-
blot analysis with the indicated antibodies.
Real-time PCR
For β-TrCP knockdown validation, RNA was isolated using PureLink 
RNA Mini Kit (Ambion, Grand Island, NY) and used as template for 
synthesis of cDNA using SuperScript II Reverse Transcriptase. The 
cDNA was subsequently used as template for quantitative RT-PCR 
analysis performed on an Applied Biosystems 7500 Fast Real-Time 
PCR System using the SYBR Green PCR kit as indicated by the manu-
facturer (Applied Biosystems). The amount of mRNA was normalized 
to Rpl32 mRNA, a housekeeping control gene. Samples were ana-
lyzed for gene expression using the following primers: β-TrCP for-
ward, 5′-ATCGGATTCCACGGTCAGAG-3′, and reverse, 5′-CTCT-
GACCGTGGAATCCGAT-3′; Rpl32, forward, 5′-AAGCGAAACTG-
GCGGAAAC-3′, and reverse, 5′-TAACCGATGTTGGGCATCAG -3′.
Immunofluorescence and live-cell time-lapse microscopy
Immunofluorescence microscopy was carried out essentially as de-
scribed in Torres et al. (2010).
HeLa stable cell lines were induced to express STARD9-MD wild 
type and serine-to- alanine mutants for 24 h, fixed with 4% parafor-
maldehyde, permeabilized with 0.2% Triton X-100/phosphate-buff-
ered saline, and costained with 0.5 μg/ml Hoechst 33342 and indi-
cated antibodies. Images were captured with a Leica DMI6000 
microscope (Leica DFC360 FX Camera, 63×/1.40–0.60 numerical 
aperture [NA] oil objective, Leica AF6000 software) at room tempera-
ture using Hoechst 3342 and secondary FITC and Cy3 antibodies 
(Jackson ImmunoResearch, West Grove, PA). Images were decon-
volved with Leica Application Suite 3D Deconvolution software and 
exported as TIFF files. For fluorescence intensity measurements, a 
3-μm circle surrounding the centrosome/spindle pole was drawn, and 
the total fluorescence intensity was measured using Leica AF6000 
software. Data represent the average ± SD of three independent ex-
periments, with 20 cells counted for each. The highest average inten-
sity (for the S317A cell line) was set to 100 and used to normalize 
the other intensity measurements. For quantifying spindle defects, 
100 cells from three independent experiments for each cell line were 
counted, and the data are presented as the average ± SD. For time-
lapse microscopy, LAP-STARD9-MD (wild-type and S317A mutant) 
cells were concurrently induced with doxycycline to express fused 
proteins and arrested with 2 mM thymidine for 18 h, washed, and 
dynamics simulation. To identify the best model, each refined struc-
ture was scored using Discrete Optimized Protein Energy (DOPE), 
and the top five models (B99990019, B99990044, B99990051, 
B99990058, and B99990090) were rescored using ERRAT potential 
by analyzing the statistics of nonbonded interactions (Colovos and 
Yeates, 1993; Shen and Sali, 2006). The best model (B99990019) was 
selected based on the combined assessment of statistical scores and 
geometric evaluation by the PROCHECK and VERIFY3D programs 
within the Structural Analysis and Verification (SAVES) server (Luthy 
et al., 1992; Laskowski et al., 1993). Model evaluation with Ramach-
andran plot shows that the final model has 92.1% residues in the 
most favorable region, 7.6% residues in the additional allowed re-
gion, and 0% residues in the disallowed region. VERIFY3D results 
show that 88% of the residues had an average 3D-1D score >0.2, 
indicating that the model is reasonable. The final STARD9 kinesin 
homology model was structurally aligned with the KIF1A template 
and visualized using the molecular modeling software Chimera 
(Pettersen et al., 2004). STARD9-MD shows strong structure similarity 
to KIF1A-MD. In particular, the ATPase catalytic site is highly con-
served. Of interest, STARD9 contains an extended loop 12 with a 
26–amino acid insertion; this loop is flexible and may play a role in 
protein–protein interactions and posttranslational modification.
Molecular modeling of the β-TrCP–STARD9-MD 
phosphodegron interaction
To model the β-TrCP–STARD9-MD interaction, the STARD9-MD de-
gron (DpSGILSpS) was structurally aligned with the β-TrCP substrate 
β-catenin within the WD40 domain (PDB 1P22:A.C). To further opti-
mize the STARD9-MD degron binding, the complex was subse-
quently energy minimized, followed by a 100-ps molecular dynamics 
simulation using the MOE software. The final peptide conformation 
was consistent with that previously reported for a nontypical degron. 
Specifically, the two phosphorylated serines pS312 and pS317 were 
anchored on two sides of the substrate-binding site through multiple 
hydrogen bonds and electrostatic interactions with residues Ser-325, 
Ser-309, Arg-285, and Ty-r271 and Arg-431, Gly-408, and Arg-410, 
respectively. The hydrogen bonds formed between S316 and Ser448 
were specific for the STARD9-MD degron, whereas that between 
D311, Arg-521, and Tyr-488 were conserved among most β-TrCP 
substrate degrons (Kanarek et al., 2010). Note that Leu-315 was in-
serted further into the inner groove through hydrophobic interac-
tions with residue Arg-474, causing loop bending.
STARD9 motor domain phosphorylation site mapping by 
liquid chromatography–tandem mass spectrometry
The LAP-STARD9-MD (wild type) cell line was grown in roller bottles, 
induced with 0.1 μg/ml doxycycline, and simultaneously arrested in 
mitosis as described (Torres et al., 2009). Cells were harvested by 
mitotic shake-off and lysed in the presence of protease (Roche, 
Branford, CT), phosphatase (Pierce, Rockford, IL), deubiquitinase 
(NEM; Enzo Lifesciences), and proteasome inhibitors (MG132; Enzo 
Lifesciences). LAP-STARD9-MD was purified from extracts using our 
tandem affinity purification protocol (Torres et al., 2009). Eluates were 
resolved on a 4–12% SDS–PAGE, and gel slices corresponding to the 
phosphorylated form of the STARD9-MD (and an adjacent control 
region) were excised and collected in a 1.5-ml tube, washed twice 
with 50% acetonitrile, flash frozen, and stored until examination by 
mass spectrometry. Mass spectrometry–based proteomic analysis of 
STARD9-MD and phosphorylation site mapping (ST: +79.9663Da) 
was performed at the Harvard Mass Spectrometry and Proteomics 
Resource Laboratory by microcapillary reverse-phase HPLC nano–
electrospray tandem mass spectrometry on a Thermo LTQ-Orbitrap 
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released into fresh media. Cells were imaged live 5 h postrelease for 
10 h using the same Leica DMI6000 microscope as described at 37°C 
and 5% CO2 using a 40×/0.75 NA air objective. To ensure good reso-
lution of the entire cell, Z-stacks were captured every 1 μm for 10 μm 
at 40× magnification, and stacks were deconvolved using Leica 3D 
deconvolution software and compressed as maximum intensity pro-
jection images. Images were converted to movies using QuickTime 
software (Apple). Each frame represents a 10-min interval.
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